Advertisement

Gastric Cancer

, Volume 22, Issue 5, pp 1016–1028 | Cite as

The predictive value of the preoperative C-reactive protein–albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data

  • Bin-bin Xu
  • Jun Lu
  • Zhi-fang Zheng
  • Jian-wei Xie
  • Jia-bin Wang
  • Jian-xian Lin
  • Qi-yue Chen
  • Long-long Cao
  • Mi Lin
  • Ru-hong Tu
  • Ze-ning Huang
  • Ju-li Lin
  • Chao-hui ZhengEmail author
  • Chang-ming HuangEmail author
  • Ping LiEmail author
Original Article
  • 345 Downloads

Abstract

Background

The definition and predictors of early recurrence (ER) for gastric cancer (GC) patients after radical gastrectomy are unclear.

Methods

A minimum-p value approach was used to evaluate the optimal cutoff value of recurrence-free survival to determine ER and late recurrence (LR). Receiver operating characteristic curves were generated for inflammatory indices. Potential risk factors for ER were assessed with a Cox regression model. A decision curve analysis was performed to evaluate the clinical utility.

Results

A total of 401 patients recruited in a clinical trial (NCT02327481) from January 2015 to April 2016 were included in this study. The optimal length of recurrence-free survival to distinguish between ER (n = 44) and LR (n = 52) was 12 months. Factors associated with ER included a preoperative C-reactive protein–albumin ratio (CAR) ≥ 0.131, stage III and postoperative adjuvant chemotherapy (PAC) > 3 cycles. The risk model consisting of both the CAR and TNM stage had a higher predictive ability and better clinical utility than TNM stage alone. Further stratification analysis of the stage III patients found that for the patients with a CAR < 0.131, both PAC with 1–3 cycles (p = 0.029) and > 3 cycles (p < 0.001) could reduce the risk of ER. However, for patients with a CAR ≥ 0.131, a benefit was observed only if they received PAC > 3 cycles (54.2% vs 16.0%, p = 0.004), rather than 1–3 cycles (58.3% vs 54.2%, p = 0.824).

Conclusions

A recurrence-free interval of 12 months was found to be the optimal threshold for differentiating between ER and LR. Preoperative CAR was a promising predictor of ER and PAC response. PAC with 1–3 cycles may not exert a protective effect against ER for stage III GC patients with CAR ≥ 0.131.

Keywords

Gastric cancer Early recurrence Adjuvant chemotherapy C-reactive protein–albumin ratio Post-recurrence survival 

Notes

Acknowledgements

This study was funded by the Scientific and Technological Innovation Joint Capital Projects of Fujian Province (2016Y9031); the National Nature Science Foundation of China (no. 81871899); the Construction Project of Fujian Province Minimally Invasive Medical Center (no. [2017]171); the second batch of Special Support Funds for Fujian Province Innovation and Entrepreneurship Talents (2016B013); the QIHANG Fund of Fujian Medical University (no. 2016QH025); the Fujian Province Medical Innovation Project (2015-CXB-16); the Fujian Provincial Health and Family Planning Commission Joint Project (WKJ2016-2-27); and the Chinese Physicians’ Association Young Physician Respiratory Research Fund.

Author contributions

JL, BX, ZZ, CHZ and CH conceived the study, analyzed the data, and drafted the manuscript. CHZ, CH and PL helped critically revise the manuscript for important intellectual content. PL, JX, JBW, JXL, QYC, LLC, ML, RHT, ZNH and JL helped collect data and design the study.

Compliance with ethical standards

Conflict of interest

All authors declare that there are no conflicts of interest or financial ties to disclose.

Human rights statement

All procedures followed were in accordance with the ethical standards of the Responsible Committee on Human Experimentation (institutional and national) and with the 1964 Declaration of Helsinki and its later versions.

Informed consent

Informed consent or a suitable substitute was obtained from all patients before being included in the study.

Supplementary material

10120_2019_936_MOESM1_ESM.docx (28 kb)
Supplementary material 1 (DOCX 27 KB)
10120_2019_936_MOESM2_ESM.tif (241 kb)
Supplementary Fig. 1 Flow chart depicting the patient selection process (TIF 241 KB)
10120_2019_936_MOESM3_ESM.tif (234 kb)
Supplementary Fig. 2 Comparison of post-recurrence survival curves between the ER and LR groups (TIF 234 KB)
10120_2019_936_MOESM4_ESM.tif (327 kb)
Supplementary Fig. 3 Comparison of the areas under the receiver operating characteristic curves for early recurrence among the inflammatory indices (TIF 326 KB)

References

  1. 1.
    Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Lin JP, Lin JX, Cao LL, et al. Preoperative lymphocyte-to-monocyte ratio as a strong predictor of survival and recurrence for gastric cancer after radical-intent surgery. Oncotarget. 2017;8(45):79234–47.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Chang JS, Kim KH, Yoon HI, et al. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. Br J Surg. 2017;104(7):877–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer. 2018;18(1):449.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lee JH, Chang KK, Yoon C, et al. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg. 2018;267(1):105–13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lee D, Son SY, Kim YB, et al. Neural invasion is a significant contributor to peritoneal recurrence in signet ring cell gastric carcinoma. Ann Surg Oncol. 2018;25(5):1167–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Yamamoto Y, Ikoma H, Morimura R, et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol. 2015;21(4):1207–15.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2018.  https://doi.org/10.1097/SLA.0000000000002734.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011;18(7):1955–63.CrossRefGoogle Scholar
  10. 10.
    Kiankhooy A, Taylor MD, LaPar DJ, et al. Predictors of early recurrence for node-negative t1 to t2b non-small cell lung cancer. Ann Thorac Surg. 2014;98(4):1175–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Otsuji E, Kobayashi S, Okamoto K, et al. Is timing of death from tumor recurrence predictable after curative resection for gastric cancer? World J Surg. 2001;25(11):1373–6.PubMedGoogle Scholar
  13. 13.
    Eom BW, Yoon H, Ryu KW, et al. Predictors of timing and patterns of recurrence after curative resection for gastric cancer. Dig Surg. 2010;27(6):481–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21(19):5934–40.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lai JF, Kim S, Kim K, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009;16(7):1896–902.CrossRefPubMedGoogle Scholar
  16. 16.
    Lu J, Zheng CH, Zheng HL, et al. Randomized, controlled trial comparing clinical outcomes of 3D and 2D laparoscopic surgery for gastric cancer: an interim report. Surg Endosc. 2017;31(7):2939–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Zheng CH, Lu J, Zheng HL, et al. Comparison of 3D laparoscopic gastrectomy with a 2D procedure for gastric cancer: a phase 3 randomized controlled trial. Surgery. 2018;163(2):300–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–9.CrossRefGoogle Scholar
  19. 19.
    Lu J, Xu BB, Zheng ZF, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric Cancer. 2018.  https://doi.org/10.1007/s10120-018-0892-0.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng ZF, Lu J, Wang W, et al. Development and external validation of a simplified nomogram predicting individual survival after R0 resection for gastric cancer: an international, multicenter study. Ann Surg Oncol. 2018;25(8):2383–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Lu J, Zheng ZF, Wang W, et al. A novel TNM staging system for gastric cancer based on the metro-ticket paradigm: a comparative study with the AJCC-TNM staging system. Gastric Cancer. 2019.  https://doi.org/10.1007/s10120-018-00904-w.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen S, Feng XY, Li YF, et al. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol. 2013;107(6):641–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Fujitani K, Tamura S, Kimura Y, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2013;17(2):348–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Jin LX, Moses LE, Squires MH 3rd, et al. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative. Ann Surg. 2015;262(6):999–1005.CrossRefPubMedGoogle Scholar
  26. 26.
    Xu BB, Lu J, Zheng ZF, et al. Comparison of short-term and long-term efficacy of laparoscopic and open gastrectomy in high-risk patients with gastric cancer: a propensity score-matching analysis. Surg Endosc. 2018.  https://doi.org/10.1007/s00464-018-6268-z.CrossRefPubMedGoogle Scholar
  27. 27.
    Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17(2):228–43.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Raftery AE. Bayesian information criterion for censored survival models.%A Volinsky CT. Biometrics. 2000;56(1):256–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ogata K, Mochiki E, Yanai M, et al. Factors correlated with early and late recurrence after curative gastrectomy for gastric cancer. Hepatogastroenterology. 2009;56(96):1760–4.PubMedGoogle Scholar
  31. 31.
    Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 2000;89(2):255–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Adachi Y, Oshiro T, Mori M, et al. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer. 1996;77(12):2445–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  34. 34.
    Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One. 2014;9(9):e106914.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–45.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Saito H, Kono Y, Murakami Y, et al. Prognostic significance of the preoperative ratio of C-reactive protein to albumin and neutrophil-lymphocyte ratio in gastric cancer patients. World J Surg. 2018;42(6):1819–25.CrossRefGoogle Scholar
  37. 37.
    Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophil–lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010;13(3):170–6.CrossRefGoogle Scholar
  38. 38.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMedGoogle Scholar
  39. 39.
    Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96(1):26–33.CrossRefPubMedGoogle Scholar
  40. 40.
    Cheong J-H, Yang H-K, Kim H, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018;19(5):629–38.CrossRefGoogle Scholar
  41. 41.
    An JY, Kim H, Cheong JH, et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2012;131(2):505–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2018.  https://doi.org/10.1097/SLA.0000000000002803.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Department of Gastric SurgeryFujian Medical University Union HospitalFuzhouChina
  2. 2.Department of General SurgeryFujian Medical University Union HospitalFuzhouChina
  3. 3.Key Laboratory of Ministry of Education of Gastrointestinal CancerFujian Medical UniversityFuzhouChina

Personalised recommendations